Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1794-1802

  Del Campo, J M ^a   Roszak, A ^b   Bidzinski, M ^c   Ciuleanu, T E ^d   Hogberg, T ^e   Wojtukiewicz, M Z ^f   Poveda, A ^g   Boman, K ^h   Westermann, A M ⁱ   Lebedinsky, C ^j  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b GREATER POLAND CANCER CENTRE   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g Valencian Institute of Oncology   (Spain)

^h UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j PHARMAMAR S A   (Spain)

more..

Author keywords

Ovarian cancer; Phase II; RECIST; Response rate; Trabectedin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM COMPLEX; TRABECTEDIN;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCYTOPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TOXIC HEPATITIS;

EID: 71049192700     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp198     Document Type: Article

References (44)

1. Carter NJ, Keam SJ. Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-2276.
2. Schöffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). Proc Am Soc Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 24, 18S (June 20 Supplement): 9522.
3. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 23: 1867-1874.
4. Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97: 1618-1624.
5. Carter NJ, Keam SJ. Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67: 2257-2276.
6. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
7. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 1584-1588.
8. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy. Oncologist 1999; 4: 87-94.
9. Katsumata N, Tsunematsu R, Tanaka K et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese cooperative study. Ann Oncol 2000; 11: 1531-1536.
10. Kaye SB, Piccart M, Aapro M et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur J Cancer 1997; 33: 2167-2170.
11. de Wit R, van der Burg ME, van den Gaast A et al. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656-657.
12. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-410.
13. Seymour MT, Mansi JL, Gallagher CJ et al. Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191-195.
14. Colombo N, Van Gorp T, Parma G et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-179.
15. Poveda A. Gemcitabine in patients with ovarian cancer. Cancer Treat Rev 2005; 31 (Suppl 4): S29-S37.
16. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890-896.
17. Baur M, Fazeny-Doerner B, Hudec M et al. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients - long-term results of a phase II study. Cancer Invest 2006; 24: 22-27.
18. Sutton GP, Blessing JA, Homesley HD et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1989; 7: 1672-1676.
19. Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995; 56: 75-78.
20. Rosenberg P, Andersson H, Boman K et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002; 41: 418-424.
21. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-2666.
22. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-1202.
23. ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-103.
24. Cantu MG, Buda A, Parma G et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20: 1232-1237.
25. Buda A, Floriani I, Rossi R et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer 2004; 90: 2112-2117.
26. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
27. Perez-Lopez ME, Curiel T, Gomez JG, Jorge M. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2007; 18: 611-617.
28. Markman M, Gordon AN, McGuire WP, Muggia FM. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004; 31: 91-105.
29. Lorusso D, Ferrandina G, Lo Voi R et al. Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer. J Chemother 2004; 16 (Suppl 4): 98-103.
30. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
31. McGuire WP, Blessing JA, Bookman MA et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18: 1062-1067.
32. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-3352.
33. Rothenberg ML, Liu PY, Wilczynski S et al. Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 2004; 95: 506-512.
34. George MJ, Heron JF, Kerbrat P et al. Navelbine in advanced ovarian epithelial cancer: A study of the French oncology centers. Semin Oncol 1989; 16: 30-32.
35. Burger RA, DiSaia PJ, Roberts JA et al. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 1999; 72: 148-153.
36. Salazar R, Vidal L, Majem M et al. Clinical and Pharmacokinetic Phase I Study of Trabectedin (T) and Carboplatin (C) in Patients with Advanced Solid Tumors. 31st European Society for Medical Oncology Congress (Istanbul, 29 September-3 October) 2006: (Abstr 424P).
37. Papadopoulos KP, Chu Q, Patnaik A et al. Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. J Clin Oncol 2006; ASCO Annual Meeting Proceedings Part I. 24, 18S (June 20 Suppl):2029.
38. Von Mehren M, Buck D, Temmer E et al. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I. 24, 18S (June 20 Suppl): 2068.
39. Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008; 14: 6656-6662.
40. Monk BJ, Herzog T, Kaye S et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol 2008; 19: viii1-viii4LBA4.
41. Mutch DG, Orlando M, Goss T et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25: 2811-2818.
42. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 2002; 7 (Suppl 5): 11-19.
43. Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. Cochrane Database Syst Rev 2008: CD005589.
44. Biagi JJ, Eisenhauer EA. Systemic treatment policies in ovarian cancer: the next 10 years. Int J Gynecol Cancer 2003; 13 (Suppl 2): 231-240.